Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim Buys 25,000 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim acquired 25,000 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was acquired at an average cost of $0.91 per share, with a total value of $22,750.00. Following the transaction, the chief financial officer now directly owns 27,400 shares of the company’s stock, valued at approximately $24,934. This represents a 1,041.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Prelude Therapeutics Price Performance

Shares of Prelude Therapeutics stock opened at $1.30 on Friday. Prelude Therapeutics Incorporated has a 1-year low of $0.80 and a 1-year high of $6.80. The company has a market capitalization of $71.55 million, a PE ratio of -0.73 and a beta of 1.49. The business has a 50-day moving average of $1.21 and a 200-day moving average of $3.17.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The business had revenue of $3.00 million for the quarter. On average, equities analysts expect that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PRLD shares. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 price objective (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Institutional Trading of Prelude Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC raised its stake in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after buying an additional 67,946 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Prelude Therapeutics by 2.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after acquiring an additional 14,226 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Prelude Therapeutics by 32.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after acquiring an additional 15,682 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Prelude Therapeutics by 103.2% during the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Prelude Therapeutics by 885.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after purchasing an additional 157,218 shares during the period. 79.72% of the stock is owned by institutional investors and hedge funds.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.